

Communication

Saliva Is a Sensitive and Accessible Sample Both for SARS-CoV-2 Detection and for the Evaluation of Treatment Effectiveness in Follow-Up Studies

Eleonora Lalle ¹, Valentina Mazzotta ² , Giuseppe Sberna ^{1,*} , Lavinia Fabeni ¹, Anna Rosa Garbuglia ¹ ,
Ilaria Mastroianni ² , Alessandra D'Abramo ² , Emanuele Nicastrì ² , Enrico Girardi ³ , Andrea Antinori ² ,
Fabrizio Maggi ¹  and Licia Bordini ¹

¹ Laboratory of Virology and Biosafety Laboratories, National Institute for Infectious Diseases Lazzaro Spallanzani—IRCCS, 00149 Rome, Italy

² Clinical and Research Department, National Institute for Infectious Diseases Lazzaro Spallanzani—IRCCS, 00149 Rome, Italy; ilaria.mastroianni@inmi.it (I.M.)

³ Scientific Direction, National Institute for Infectious Diseases Lazzaro Spallanzani—IRCCS, 00149 Rome, Italy

* Correspondence: giuseppe.sberna@inmi.it; Tel.: +39-0655170696

Abstract: Despite emerging evidence indicating that molecular SARS-CoV-2 tests performed on saliva have diagnostic sensitivity and specificity comparable to those observed with nasopharyngeal swabs (NPSs), most in vivo follow-up studies on the efficacy of drugs against SARS-CoV-2 have been performed on NPSs, not considering saliva as a possible alternative matrix. For this reason, in this study, we used, in parallel, saliva and NPS samples for the detection of SARS-CoV-2 by real-time RT-PCR in patients receiving Tixagevimab/Cilgavimab, Nirmatrelvir/Ritonavir, or Sotrovimab as a treatment against SARS-CoV-2. Our results showed a good correlation between the NPS and saliva samples for each drug; moreover, comparable changes in the cycle threshold (Ct) levels in saliva and NPSs were observed both 7 days and 30 days after treatment, thus confirming that the saliva represents a good matrix for in vivo follow-up studies verifying the effectiveness of treatments against SARS-CoV-2.

Keywords: SARS-CoV-2; molecular assay; saliva; COVID-19 diagnosis; monoclonal antibodies; antiviral therapy; follow-up studies



Citation: Lalle, E.; Mazzotta, V.; Sberna, G.; Fabeni, L.; Garbuglia, A.R.; Mastroianni, I.; D'Abramo, A.; Nicastrì, E.; Girardi, E.; Antinori, A.; et al. Saliva Is a Sensitive and Accessible Sample Both for SARS-CoV-2 Detection and for the Evaluation of Treatment Effectiveness in Follow-Up Studies. *Viruses* **2024**, *16*, 1040. <https://doi.org/10.3390/v16071040>

Academic Editor: Francesca Esposito

Received: 23 May 2024

Revised: 18 June 2024

Accepted: 26 June 2024

Published: 27 June 2024



Copyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Despite its prominence in early scientific records, the usefulness of saliva as a respiratory specimen has been de-emphasized over the past century. Before the COVID-19 pandemic, several studies had already refreshed the potential of saliva for detecting seasonal respiratory viruses. Notably, despite the positive results obtained by these studies, little work has been carried out to further elucidate the possible role of this matrix for diagnostic purposes [1]. Increasing evidence has emerged during the COVID-19 pandemic indicating that molecular tests performed on saliva have diagnostic sensitivity and specificity comparable, or even superior, to those observed with a nasopharyngeal swab (NPS) for SARS-CoV-2 detection [2–9]. Based on this evidence, numerous efforts have been made to develop and implement saliva-based diagnostic tests aimed at expanding the use of saliva in clinical settings [10].

Looking towards the future, as saliva uniquely contains both respiratory secretions and immunological components, it has potentially wide applications, ranging from clinical diagnostics to post-vaccine disease burden and immunity surveillance. Due to its easy, painless self-collection and viral stability, saliva represents a suitable alternative sample, especially in community mass-screening programs and the longitudinal sampling of hospitalized individuals aimed at monitoring viral load dynamics and treatment response.

Since the beginning of the SARS-CoV-2 pandemic, the entire scientific world has been developing vaccines, representing an optimal method of pre-exposure prophylaxis. Nevertheless, after four doses, immunocompromised individuals show a reduced vaccine response [11–14]. In this context, regimens of monoclonal antibodies (mAbs) or antiviral agents have been developed, which are useful as a treatment against COVID-19 and provide passive immunization to boost immunity against SARS-CoV-2.

Over time, several drugs have been used for the treatment of SARS-CoV-2, including the direct-acting antivirals (DAAs) remdesivir (RDV), molnupiravir (MNP), and ritonavir-boosted nirmatrelvir (NRM), as well as anti-spike monoclonal antibodies (mAbs; i.e., Tixagevimab/Cilgavimab or Sotrovimab) [15].

Numerous studies have analyzed how the efficacy of mAbs and antivirals, initially produced against early SARS-CoV-2 variants, has changed over time, with new variants, especially the Omicron subvariants [16–20]. Scientific evidence highlighted that continued virus evolution has progressively decreased or abolished mAbs' neutralization activity, with few cases of restored activity against the currently dominating virus lineages [21]; on the other hand, DAA seemed to have maintained their activity across multiple variants due to the high conservation of the targeted viral enzymes [22].

In most of these *in vivo* follow-up studies, the virological outcome of treatment with mAbs, antivirals, or multiple combination therapies has been evaluated by measuring viral loads in NPSs [23–27].

Here, we investigated the possible use of saliva samples as a surrogate of NPSs in *in vivo* follow-up studies in COVID-19 patients receiving Tixagevimab/Cilgavimab, Nirmatrelvir/Ritonavir, or Sotrovimab, in order to establish the effectiveness of different treatments.

2. Materials and Methods

2.1. Study Population

Sixty patients who accessed the National Institute for Infectious Diseases “L. Spallanzani” from March to May 2022 were included in this study, with a median time from symptom onset of 3 days (IQR 2–4). None of the patients was hospitalized, since all of them had mild-to-moderate COVID-19. The enrolled patients met the Italian Pharmaceutical Agency (AIFA) criteria for eligibility for treatment with monoclonal antibodies or antiviral agents. Treatment allocation was dependent on drug availability, time since symptom onset, and the presence of comorbidities as defined by the AIFA criteria. The patients were selected from a larger cohort previously described [28] based on the administered therapy, homogeneous sex, and a similar mean age: 20 patients received Tixagevimab/Cilgavimab (10 men and 10 female patients, mean $\pm$ SD: 58.80 ± 15.83), 20 Nirmatrelvir/Ritonavir (10 men and 10 female patients, mean $\pm$ SD: 66.80 ± 12.52), and 20 Sotrovimab (10 men and 10 female patients, mean $\pm$ SD: 62.95 ± 13.17).

The patients were attested in a follow-up at three time points: before drug administration (T0), on day 7 (T7), and on day 30 (T30) after treatment initiation. Data from the biological samples were used only after complete anonymization.

2.2. Sample Collection

Two mL of saliva was self-collected, under medical personal supervision, by passive drooling, spontaneously produced without external stimuli, in sterile containers without any buffer added, at least 30 min after drinking, eating, or brushing one's teeth. NPSs were put into sterile tubes containing 2–3 mL of viral transport media (Copan UTM[®] Universal Transport Medium, Copan Diagnostics Italia s.p.a., Brescia, Italy). The NPS and saliva samples were collected simultaneously and immediately processed.

2.3. SARS-CoV-2 Real-Time PCR

The NPS and saliva samples were tested using an Alinity mSARS-CoV-2 AMP assay (Abbott Diagnostics GmbH, Wiesbaden, Germany), targeting RdRp and N. Briefly, the NPSs were directly loaded on the Alinity instrument using a lysis solution, while the saliva

samples had been previously diluted with the Alinity m Specimen Diluent (diluent volume ratio of 1:1.25).

2.4. Sequence Analysis

The genetical characterization of SARS-CoV-2 variants was performed on the saliva and/or NPS samples by Sanger sequencing. The extraction of viral RNA was performed using the automated QiaSymphony system (Qiagen Instruments AG Switzerland, Hilden, Germany), according to the manufacturer's instructions. The amplified products of the fragment corresponding to the aminoacidic coverage 399–616 of the SARS-CoV-2 spike gene obtained by means of a one-step RT-PCR kit (Qiagen) were sequenced using the Big Dye Terminator Cycle Sequencing kit v3.1 (Applied Biosystems, Foster City, CA, USA) and an automatic DNA sequencer (ABI model 3130 and/or 3500 XL, Applied Biosystems, Foster City, CA, USA). The sequences were compared by alignment with the original Wuhan virus sequence (accession number: NC_045512.2) [7].

2.5. Statistical Analysis

Data management and analyses were performed using GraphPad Prism version 9.3.1 (GraphPad Software, La Jolla, CA, USA). The characterization of the patients enrolled in this study was performed by descriptive analysis.

The correlation between the cycle threshold (Ct) values obtained in the NPSs and the Ct obtained in the saliva was calculated by a linear regression analysis, with negative samples assigned an arbitrary value of 42 Ct, with 40 Ct set as the detection limit of the assay.

3. Results

The study population, genetically characterized as SARS-CoV-2 BA.1 (83.3%), BA.2 (15%), and BA.5 (1.7%) variants, was stratified based on the different SARS-CoV-2 treatments received (20 patients treated with Tixagevimab/Cilgavimab, 20 patients with Sotrovimab, and 20 patients with Nirmatrelvir/Ritonavir), and the correlation between the Ct values obtained in the NPS versus saliva matrices was evaluated (Figure 1). As shown in Figure 1, a statistically significant correlation was observed for both the mAb (Tixagevimab/Cilgavimab: $r = 0.8162$, $p < 0.0001$ panel A; Sotrovimab: $r = 0.8610$, $p < 0.0001$, panel B) and antiviral treatments (Nirmatrelvir/Ritonavir: $r = 0.8134$, $p < 0.0001$, panel C).




Figure 1. Linear regression analysis in NPS and saliva samples in patients receiving Tixagevimab/Cilgavimab (A), Sotrovimab (B), or Nirmatrelvir/Ritonavir (C).

Moreover, the Ct reduction during the follow-up period was examined, measuring T7 or T30 minus T0, both in the saliva (Figure 2, Panel A) and NPSs (Figure 2, Panel B).

Specifically, when analyzing the Ct values at T7 minus T0, in the saliva matrix, the mean reduction was -13.23 (SEM: ± 1.13) Ct after treatment with Nirmatrelvir/Ritonavir, -11.12 (SEM: ± 1.54) Ct following Tixagevimab/Cilgavimab, and -8.52 (SEM: ± 0.90) Ct following Sotrovimab. The same analysis was performed on the NPSs, showing a mean Ct reduction of -14.92 (SEM: ± 1.31), -9.89 (SEM: ± 1.53), and -10.96 (SEM: ± 1.51), respectively.




Figure 2. Mean of Ct reduction in saliva samples (A) and NPSs (B) at T0, T7, and T30, compared to T0, according to the three different treatments. SEM: standard error of the mean. Tixagevimab/Cilgavimab in blue, Sotrovimab in green, and Nirmatrelvir/Ritonavir in red.

When analyzing the Ct values at T30 minus T0, the saliva matrix showed a mean Ct reduction of -16.86 (SEM: ± 1.10) Ct after treatment with Nirmatrelvir/Ritonavir, -17.27 (SEM: ± 1.04) Ct with Tixagevimab/Cilgavimab, and -15.32 (SEM: ± 1.10) Ct with Sotrovimab. Looking at the NPSs, means of -22.45 (SEM: ± 1.11), -23.44 (SEM: ± 0.77), and -23.62 (SEM: ± 0.74) were observed, respectively.

4. Discussion

During the COVID-19 pandemic, a growing consensus emerged on the use of saliva as an effective, stable, low-cost, and non-invasive matrix to detect SARS-CoV-2 RNA [8]. Even though saliva tests were thought to be less sensitive than NPS tests, many studies have since shown that the molecular tests for SARS-CoV-2 detection performed on saliva are comparable in terms of diagnostic sensitivity and specificity to NPSs [3,28,29]. Nevertheless, most in vivo follow-up studies on the efficacy of drugs against COVID-19 have been performed on NPSs, not considering saliva as a possible alternative matrix.

In this study, we analyzed 60 patients receiving Tixagevimab/Cilgavimab, Nirmatrelvir/Ritonavir, or Sotrovimab as an early treatment against COVID-19, testing, in parallel, oral saliva and NPS samples to evaluate the virological outcome of the treatment by real-time RT-PCR.

When stratifying the study population based on the different COVID-19 treatments received, a statistically significant correlation between the saliva and NPS samples was observed for both the mAb (Tixagevimab/Cilgavimab, Sotrovimab) and antiviral treatments (Nirmatrelvir/Ritonavir), confirming that both matrices are eligible for SARS-CoV-2 RNA detection.

Moreover, the mean Ct reduction at T7 minus T0 was comparable in both matrices for each treatment, while a minor mean Ct reduction at T30 minus T0 was observed in the saliva samples versus the NPSs for all the treatments. This latter finding could be because the mean Ct in the saliva samples was already higher at T0 than the mean Ct in the NPSs, and this difference was proportionally maintained in the subsequent observation times. Nonetheless, the average change in Ct between the two matrices remained the same during all follow-up periods. It is worth underlining that the mean Ct values at T30 for both matrices exceeded 40 Ct, indicating a viral load at the limit of detectability.

Overall, the linear regression analyses indicated a high concordance between the Ct values obtained in the saliva and NPS matrices after mAb or antiviral treatment. According to published data, we observed mean Ct values in NPSs lower than in saliva at T0 and at the following time points [30]. However, the mean Ct reduction after drug administration was

comparable in both matrices, thus suggesting that saliva could represent a valid alternative matrix for in vivo follow-up studies to evaluate the effectiveness of treatments against COVID-19. Increasing the number of patients, treatments, and follow-up times in studies can help confirm our results and fully define how accurate saliva tests are.

Author Contributions: Conceptualization, L.B.; formal analysis, L.B., G.S., E.L. and L.F.; resources, V.M. and A.A.; data curation, G.S.; writing—original draft preparation, G.S.; writing—review and editing, L.B. and F.M.; visualization, E.L., V.M., A.R.G., I.M. and A.D.; supervision: E.N., E.G., A.A. and F.M.; funding acquisition, E.G. and F.M. All authors have read and agreed to the published version of the manuscript.

Funding: This study was supported by funds allocated to the National Institute for Infectious Diseases “Lazzaro Spallanzani”, IRCCS, Rome (Italy), from the Italian Ministry of Health (Program CCM 2020 Ricerca Corrente—Linea 1 on emerging and re-emerging infections).

Institutional Review Board Statement: This study was conducted in accordance with the Declaration of Helsinki and approved by the Scientific Committee of the Italian Medicine Agency (AIFA) and the Ethical Committee of the National Institute for Infectious Diseases “Lazzaro Spallanzani” IRCCS, Rome (Italy), as the National Review Board for the COVID-19 pandemic in Italy (approval number 380/2021). The data from the biological samples collected for diagnostic purposes were used only after their complete anonymization. Furthermore, the analysis of genetic data was not provided.

Informed Consent Statement: Informed consent was obtained from all the subjects involved in this study.

Data Availability Statement: The original contributions presented in this study are included in the article; further inquiries can be directed to the corresponding author.

Conflicts of Interest: The authors declare no conflicts of interest.

References

- To, K.K.W.; Yip, C.C.Y.; Lai, C.Y.W.; Wong, C.K.H.; Ho, D.T.Y.; Pang, P.K.P.; Ng, A.C.K.; Leung, K.H.; Poon, R.W.S.; Chan, K.H.; et al. Saliva as a diagnostic specimen for testing respiratory virus by a point-of-care molecular assay: A diagnostic validity study. *Clin. Microbiol. Infect.* **2019**, *25*, 372–378. [CrossRef] [PubMed]
- Tan, S.H.; Allicock, O.; Armstrong-Hough, M.; Wyllie, A.L. Saliva as a gold-standard sample for SARS-CoV-2 detection. *Lancet Respir. Med.* **2021**, *9*, 562–564. [CrossRef] [PubMed]
- Butler-Laporte, G.; Lawandi, A.; Schiller, I.; Yao, M.; Dendukuri, N.; McDonald, E.G.; Lee, T.C. Comparison of Saliva and Nasopharyngeal Swab Nucleic Acid Amplification Testing for Detection of SARS-CoV-2: A Systematic Review and Meta-analysis. *JAMA Intern. Med.* **2021**, *181*, 353–360. [CrossRef] [PubMed]
- Caixeta, D.C.; Oliveira, S.W.; Cardoso-Sousa, L.; Cunha, T.M.; Goulart, L.R.; Martins, M.M.; Marin, L.M.; Jardim, A.C.G.; Siqueira, W.L.; Sabino-Silva, R. One-Year Update on Salivary Diagnostic of COVID-19. *Front. Public Health* **2021**, *9*, 589564. [CrossRef] [PubMed]
- Tobik, E.R.; Kitfield-Vernon, L.B.; Thomas, R.J.; Steel, S.A.; Tan, S.H.; Allicock, O.M.; Choate, B.L.; Akbarzada, S.; Wyllie, A.L. Saliva as a sample type for SARS-CoV-2 detection: Implementation successes and opportunities around the globe. *Expert Rev. Mol. Diagn.* **2022**, *22*, 519–535. [CrossRef] [PubMed]
- McPhillips, L.; MacSharry, J. Saliva as an alternative specimen to nasopharyngeal swabs for COVID-19 diagnosis: Review. *Access Microbiol.* **2022**, *4*, acmi000366. [CrossRef] [PubMed]
- Sberna, G.; Fabeni, L.; Berno, G.; Carletti, F.; Specchiarello, E.; Colavita, F.; Meschi, S.; Matusali, G.; Garbuglia, A.R.; Bordi, L.; et al. Rapid and qualitative identification of SARS-CoV-2 mutations associated with variants of concern using a multiplex RT-PCR assay coupled with melting analysis. *Int. J. Infect. Dis.* **2022**, *122*, 401–404. [CrossRef] [PubMed]
- Laxton, C.S.; Peno, C.; Hahn, A.M.; Allicock, O.M.; Perniciaro, S.; Wyllie, A.L. The potential of saliva as an accessible and sensitive sample type for the detection of respiratory pathogens and host immunity. *Lancet Microbe* **2023**, *4*, e837–e850. [CrossRef]
- Castillo-Bravo, R.; Lucca, N.; Lai, L.; Marlborough, K.; Brychkova, G.; Sakhteh, M.S.; Lonergan, C.; O’Grady, J.; Alikhan, N.F.; Trotter, A.J.; et al. Clinical Performance of Direct RT-PCR Testing of Raw Saliva for Detection of SARS-CoV-2 in Symptomatic and Asymptomatic Individuals. *Microbiol. Spectr.* **2022**, *10*, e0222922. [CrossRef]
- FIND. Available online: <https://www.finddx.org/covid-19/> (accessed on 26 March 2024).
- Rusk, D.S.; Strachan, C.C.; Hunter, B.R. Lack of immune response after mRNA vaccination to SARS-CoV-2 in a solid organ transplant patient. *J. Med. Virol.* **2021**, *93*, 5623–5625. [CrossRef]
- Prundecki, M.; Clarke, C.; Edwards, H.; McIntyre, S.; Mortimer, P.; Gleeson, S.; Martin, P.; Thomson, T.; Randell, P.; Shah, A.; et al. Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression. *Ann. Rheum. Dis.* **2021**, *80*, 1322–1329. [CrossRef] [PubMed]

13. Dumortier, J.; Duvoux, C.; Roux, O.; Altieri, M.; Barraud, H.; Besch, C.; Caillard, S.; Coilly, A.; Conti, F.; Dharancy, S.; et al. COVID-19 in liver transplant recipients: The French SOT COVID registry. *Clin. Res. Hepatol. Gastroenterol.* **2021**, *45*, 101639. [[CrossRef](#)] [[PubMed](#)]
14. Belsky, J.A.; Tullius, B.P.; Lamb, M.G.; Sayegh, R.; Stanek, J.R.; Auletta, J.J. COVID-19 in immunocompromised patients: A systematic review of cancer, hematopoietic cell and solid organ transplant patients. *J. Infect.* **2021**, *82*, 329–338. [[CrossRef](#)] [[PubMed](#)]
15. Mustafa, S.S.; Stern, R.A.; Patel, P.C.; Chu, D.K. COVID-19 Treatments: Then and Now. *J. Allergy Clin. Immunol. Pract.* **2023**, *11*, 3321–3333. [[CrossRef](#)] [[PubMed](#)]
16. Benotmane, I.; Velay, A.; Gautier-Vargas, G.; Olagne, J.; Thaunat, O.; Fafi-Kremer, S.; Caillard, S. Pre-exposure prophylaxis with 300 mg Evusheld elicits limited neutralizing activity against the Omicron variant. *Kidney Int.* **2022**, *102*, 442–444. [[CrossRef](#)] [[PubMed](#)]
17. Cao, Y.; Wang, J.; Jian, F.; Xiao, T.; Song, W.; Yisimayi, A.; Huang, W.; Li, Q.; Wang, P.; An, R.; et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. *Nature* **2022**, *602*, 657–663. [[CrossRef](#)] [[PubMed](#)]
18. Bruel, T.; Hadjadj, J.; Maes, P.; Planas, D.; Seve, A.; Staropoli, I.; Guivel-Benhassine, F.; Porrot, F.; Bolland, W.H.; Nguyen, Y.; et al. Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies. *Nat. Med.* **2022**, *28*, 1297–1302. [[CrossRef](#)] [[PubMed](#)]
19. Davis, J.A.; Granger, K.; Roubal, K.; Smith, D.; Gaffney, K.J.; McGann, M.; Cendagorta, A.; Thurlapati, A.; Herbst, A.; Hendrickson, L.; et al. Efficacy of tixagevimab-cilgavimab in preventing SARS-CoV-2 for patients with B-cell malignancies. *Blood* **2023**, *141*, 200–203. [[CrossRef](#)]
20. Planas, D.; Saunders, N.; Maes, P.; Guivel-Benhassine, F.; Planchais, C.; Buchrieser, J.; Bolland, W.H.; Porrot, F.; Staropoli, I.; Lemoine, F.; et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. *Nature* **2022**, *602*, 671–675. [[CrossRef](#)]
21. Touret, F.; Giraud, E.; Bourret, J.; Donati, F.; Tran-Rajau, J.; Chiaravalli, J.; Lemoine, F.; Agou, F.; Simon-Lorière, E.; van der Werf, S.; et al. Enhanced neutralization escape to therapeutic monoclonal antibodies by SARS-CoV-2 omicron sub-lineages. *iScience* **2023**, *26*, 106413. [[CrossRef](#)]
22. Cho, J.; Shin, Y.; Yang, J.S.; Kim, J.W.; Kim, K.C.; Lee, J.Y. Evaluation of antiviral drugs against newly emerged SARS-CoV-2 Omicron subvariants. *Antivir. Res.* **2023**, *214*, 105609. [[CrossRef](#)] [[PubMed](#)]
23. Gidari, A.; Sabbatini, S.; Schiaroli, E.; Bastianelli, S.; Pierucci, S.; Busti, C.; Comez, L.; Libera, V.; Macchiarulo, A.; Paciaroni, A.; et al. The Combination of Molnupiravir with Nirmatrelvir or GC376 Has a Synergic Role in the Inhibition of SARS-CoV-2 Replication In Vitro. *Microorganisms* **2022**, *10*, 1475. [[CrossRef](#)] [[PubMed](#)]
24. Tepas, P.R.; Hafezi, W.; Lutz, M.; Kühn, J.; Wilms, C.; Wiewrodt, R.; Sackarnd, J.; Keller, M.; Schmidt, H.H.; Vollenberg, R. Persisting SARS-CoV-2 viraemia after rituximab therapy: Two cases with fatal outcome and a review of the literature. *Br. J. Haematol.* **2020**, *190*, 185–188. [[CrossRef](#)] [[PubMed](#)]
25. Mazzotta, V.; Cozzi Lepri, A.; Colavita, F.; Rosati, S.; Lalle, E.; Cimaglia, C.; Paulicelli, J.; Mastroi, I.; Vita, S.; Fabeni, L.; et al. Viral load decrease in SARS-CoV-2 BA.1 and BA.2 Omicron sublineages infection after treatment with monoclonal antibodies and direct antiviral agents. *J. Med. Virol.* **2023**, *95*, e28186. [[CrossRef](#)] [[PubMed](#)]
26. Mazzotta, V.; Cozzi-Lepri, A.; Colavita, F.; Lanini, S.; Rosati, S.; Lalle, E.; Mastroi, I.; Cimaglia, C.; Vergori, A.; Bevilacqua, N.; et al. Emulation of a Target Trial from Observational Data to Compare Effectiveness of Casirivimab/Imdevimab and Bamlanivimab/Etesevimab for Early Treatment of Non-Hospitalized Patients with COVID-19. *Front. Immunol.* **2022**, *13*, 868020. [[CrossRef](#)] [[PubMed](#)]
27. Chew, K.W.; Moser, C.; Daar, E.S.; Wohl, D.A.; Li, J.Z.; Coombs, R.; Ritz, J.; Giganti, M.; Javan, A.C.; Li, Y.; et al. Bamlanivimab reduces nasopharyngeal SARS-CoV-2 RNA levels but not symptom duration in non-hospitalized adults with COVID-19: A Phase 2 Randomized Clinical Trial. *medRxiv* **2021**. [[CrossRef](#)]
28. Bordi, L.; Sberna, G.; Lalle, E.; Fabeni, L.; Mazzotta, V.; Lanini, S.; Corpolongo, A.; Garbuglia, A.R.; Nicastri, E.; Girardi, E.; et al. Comparison of SARS-CoV-2 Detection in Nasopharyngeal Swab and Saliva Samples from Patients Infected with Omicron Variant. *Int. J. Mol. Sci.* **2023**, *24*, 4847. [[CrossRef](#)]
29. Bordi, L.; Sberna, G.; Lalle, E.; Piselli, P.; Colavita, F.; Nicastri, E.; Antinori, A.; Boumis, E.; Petrosillo, N.; Marchioni, L.; et al. Frequency and Duration of SARS-CoV-2 Shedding in Oral Fluid Samples Assessed by a Modified Commercial Rapid Molecular Assay. *Viruses* **2020**, *12*, 1184. [[CrossRef](#)]
30. Ahti, J.; Österback, R.; Keskitalo, A.; Makkala, K.; Vidbäck, S.; Veikkolainen, V.; Vuorinen, T.; Peltola, V.; Hakanen, A.J.; Waris, M.; et al. Diagnostic Performance and Tolerability of Saliva and Nasopharyngeal Swab Specimens in the Detection of SARS-CoV-2 by RT-PCR. *Microbiol. Spectr.* **2023**, *11*, e0532422. [[CrossRef](#)]

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.